Investors

Poised for Rapid Growth

Nanochon is redefining the treatment landscape for cartilage repair with the Chondrograft™ implant — an innovative, synthetic device designed for pre-replacement patients: adults with significant cartilage damage who are too young for total knee replacement but need more than short-term or palliative treatments.

Nanochon is pursing to fill the market need where current standard of care falls short.

Our solution, Chondrograft™, is an easy-to-use, innovative surgical implant and burn-no-bridges solution that can quickly return patients to a full quality of life after a minimally invasive procedure.

Why It Matters

Cartilage does not heal on its own. When patients experience cartilage injuries, they face limited, costly, and often invasive treatment options — and left untreated, the condition worsens into osteoarthritis, eventually requiring joint replacement. Yet even joint replacements are temporary and tend to fail in active patients.

Nanochon’s Chondrograft™ is designed to fill this critical treatment gap, providing surgeons with an easy-to-use, off-the-shelf solution that restores function and supports natural tissue repair, helping patients return to full activity faster.

Market Opportunity

We estimate a $2 billion annual target market in the U.S. alone, based on a patient population of nearly half a million individuals who fit our initial indication.

Looking beyond the knee, similar cartilage defects occur in other large joints such as the ankle, shoulder, and hip, representing an expanded $4 billion annual opportunity.

In total, we believe the underlying technology could support applications across a $10 billion global market when tailored for other sizes and uses.

Our Advantage

Unlike cadaver tissue grafts and cell-based therapies, Nanochon’s implant is fully synthetic, sterile, and shelf-stable, eliminating logistical challenges and long wait times.

Advanced Manufacturing

Our proprietary material and 3D printing process allow us to produce complex, mechanically robust implants that serve both as immediate replacements and repairing scaffolds.

Clinically Relevant Design

Developed with surgeon needs in mind, our implant and surgical tools are ready for straightforward, high-volume use in orthopedic practice.

Progress and Milestones

Nanochon has completed three successful animal studies, including a 12-month horse study (a model known for developing osteoarthritic-like degeneration). The results demonstrated robust material performance, cartilage integration, and bone reconstitution over time.

In 2025, Nanochon has received regulatory and research ethics board approvals to launch our first human clinical study in Canada: a 10-patient safety trial with one-year follow-up.

Looking ahead, we plan to raise a $20 million Series A to support a Level 1 North American Pivotal Study.